First China-Made Rapid-Acting Insulin Wins US FDA ApprovalYicai·Jul 28 at 05:28 AM600867+0.36%603707-0.61%
Adocia Notifies Availability of Q2 2026 Financial Results Press ReleasePUBT·Jul 23 at 11:00 AMSNY+0.44%600867+0.36%
THDB: The winter insulin injection has obtained an overseas drug registration certificateZhitong·Oct 24, 2025 at 02:46 AM600867+0.36%
THDB: Announced the shareholding status of the top ten shareholders and the top ten unrestricted shareholders before the share repurchaseZhitong·Oct 22, 2025 at 03:25 AM600867+0.36%
THDB plans to repurchase company shares for between 20 million and 40 million yuanZhitong·Oct 17, 2025 at 03:46 AM600867+0.36%
THDB: Insulin Glargine Injection has obtained overseas listing approvalZhitong·Oct 10, 2025 at 04:07 AM600867+0.36%
THDB: The domestic insulin market will continue to develop steadily in the next three yearsZhitong·Oct 9, 2025 at 02:57 AM600867+0.36%
China Galaxy Securities: The future domestic substitution space for diabetes is broad, and innovation is expected to achieve a curve overtakingZhitong·Sep 10, 2025 at 08:23 PM600867+0.36%603087+1.22%
THDB plans to launch an employee stock ownership plan in 2025Zhitong·Sep 2, 2025 at 07:26 AM600867+0.36%
THDB released its semi-annual performance, with a net profit attributable to the parent company of 218 million yuan, turning a profit from a loss year-on-yearZhitong·Aug 25, 2025 at 07:42 AM600867+0.36%
THDB: Preliminary net profit data for the first half of the year is RMB 217.3 millionZhitong·Jul 14, 2025 at 02:35 AM600867+0.36%
Tofflon and THDB signed a strategic cooperation agreementZhitong·Jun 30, 2025 at 07:46 PM600867+0.36%300171+0.66%
"Major Banks" CMB International's Investment Ratings and Target Prices for Pharmaceutical Stocks (Table)AASTOCKS·Jun 23, 2025 at 02:11 AMBGNE0.00%688235-0.95%
THDB plans to transfer 5.7% of its shares in TeBao Bio at a price of 1.301 billion yuanZhitong·May 22, 2025 at 06:39 AM600867+0.36%
